The present disclosure relates to sVERO 7C2, which is a Vero cell line derived from Vero cells (African Green Monkey Kidney Cell Line) distributed from the WHO and capable of suspension culture without serum components. Further, the present disclosure relates to a culture method for growing the Vero cells and a method for producing a vaccine virus using the Vero cells.

Provided is a three-dimensional tissue, including: a first cellular region including cells of a first type; and a second cellular region including cells of a second type different from the first type, wherein the cells of the first type are cells that emit light by chemiluminescence, bioluminescence, or fluorescence in response to an external stimulus.

A three-dimensional cell culture platform includes a cell supporting medium having at least one microwell formed therein; and one or more microwell spacers defining an entrance of the or each microwell, the entrance enabling the introduction of a cell culture medium into the or each microwell. The volume of a microwell is determined by a surface of the one or more microwell spacers defining the entrance of the microwell, and by an interface of the cell supporting medium of the microwell. The one or more microwell spacers are in direct contact with the cell supporting medium prior to one or more cells being delivered to the three-dimensional cell culture platform.

Provided is a 3D human liver organ model constructing method, comprising: preparing human primary liver cells, or mixed cells of same and liver non-parenchymal cells, or human liver cancer cell lines into a single cell suspension, and mixing the single cell suspension with a matrix material to obtain a mixed cell suspension; inoculating the mixed cell suspension into cultivation micropores of a 3D organ-on-a-chip, and carrying out cultivation at 37° C. to obtain a gelled 3D organ-on-a-chip; adding a culture medium into liquid storage holes of the organ-on-a-chip, and carrying out cultivation to obtain a 3D human liver organ model. Compared with other 2D human liver organ models, the constructed 3D human liver organ model has significantly enhanced response sensitivity to hepatotoxic drugs, and shows stronger hepatotoxic damage effect for reported hepatotoxic drugs. Compared with an animal model, the 3D human liver organ model can effectively eliminate the screening difference caused by species difference.

A drug screening platform simulating hyperthermic intraperitoneal chemotherapy including a dielectrophoresis system, a microfluidic chip and a heating system is disclosed. The dielectrophoresis system is used to provide a dielectrophoresis force. The microfluidic chip includes a cell culture array and observation module and a drug mixing module. The cell culture array and observation module are used to arrange the cells into a three-dimensional structure through the dielectrophoresis force to construct a three-dimensional tumor microenvironment. The drug mixing module is coupled to the cell culture array and observation module and used to automatically split and mix the inputted drugs and output the drug combinations into the cell culture array and observation module. The heating system is used for real-time temperature sensing and heating control of the drug combinations on the microfluidic chip to simulate high-temperature drug environment when performing hyperthermic intraperitoneal chemotherapy on the three-dimensional tumor microenvironment.

The invention relates to the use of matrix cells for obtaining a micro hair follicle and to the use thereof for evaluating the effect of cosmetic, pharmaceutical or dermatological products and also for the prophylactic or therapeutic treatment of a state of reduced pilosity.

A transfer device designed to extract an amorphous or semi-solid structure, tissue, or construct from supporting media while maintaining the spatial integrity/organizational architecture thereof. The transfer device can include a controller, an actuator assembly, a plunger, and a needle. The controller can move the transfer device and the plunger independently.

A composition includes porous silica particles to carry a cell fate modulating factor therein. A method for modulating cell fate includes treating various cells with the composition. The cell fate modulating factor is delivered to a stable target receptor, toxicity to subject cells for delivery may be reduced, a fate of the subject cells can be controlled through sustained release of at least 99 wt. % of the cell fate modulating factor.

The present invention provides a method for producing a unilocular adipocyte including inducing differentiation into unilocular adipocytes of mesenchymal cells having differentiation potency into adipocytes by culturing the mesenchymal cells in suspension in a liquid medium composition capable of culturing cells or tissues in suspension, wherein the liquid medium composition contains a polymer compound having an anionic functional group that binds via a divalent metal cation to form a structure capable of suspending cells or tissues, and the method wherein the polymer compound is polysaccharide, preferably polysaccharide containing a glucuronic acid moiety, more preferably deacylated gellan gum, diutan gum or xanthan gum or a salt thereof.

A method of obtaining 3D cell structures including differentiated human hepatic cells. The method includes: a first step of culturing stem cell-derived or immortalized human hepatic progenitors in a non-adherent culture vessel, preferably a low or ultra-low attachment culture vessel; a second step of transferring the stem cell-derived or immortalized human hepatic progenitors to a culture medium including methacrylated gelatin (GelMa), thereby embedding the stem cell-derived or immortalized human hepatic progenitors in a GelMa matrix; and a third step of covering the GelMa matrix with culture medium and culturing the stem cell-derived or immortalized human hepatic progenitors embedded in the GelMa matrix, thereby obtaining 3D cell structures including differentiated human hepatic cells. Also, methods for engineering an artificial liver model or an artificial liver organ, and for assessing in vitro the metabolism, toxicity and/or therapeutic effects of a compound.